View the results of last month's survey and VOTE a new January survey!

Five amazing course options await those who participate in the JDRF Ride to Cure Diabetes in 2017.

Follow up data on both old and new diabetes clinical trials shows there is long-term benefit to early intervention in treating diabetes.

Children and adolescents age 1 and up now have another option in basal insulin. On December 19, 2016, Novo Nordisk announced that the FDA approved an expanded indication for Tresiba (insulin degludec injection 100 U/mL, 200 U/mL).

If you have gastroparesis, a new treatment option might be available sooner than you'd think.

After more than a decade of advocacy efforts, Medicare will finally start to cover CGM. However, coverage will be determined on a case-by-case basis. Are you CGM-Worthy???

If you are paying full retail pricing at the pharmacy for insulin because you do not have insurance, or are in the deductible phase of your high-deductible insurance plan, you may soon be able to get a little relief.

We are all so eager for a commercially available closed-loop "bionic pancreas" system to hit the market. But glucagon isn't stable for any great length of time after it is reconstituted, so researchers are working on developing a more stable version of it. Read on to learn more about progress on that front!